The problem to solve
CNS therapies often face a tension between efficacious dose, systemic exposure and tolerability.
PLATFORM 01
CNS Complex Formulation & Biomimetic Evaluation
An integrated delivery, device, biomimetic-model and in vivo evidence loop centered on exposure efficiency and therapeutic window.
Platform approach
Complex formulation and biomimetic evaluation map deposition, permeation, exposure, efficacy and safety to accelerate candidate convergence.
Core functional modules
Complex formulation design2.5D/3D biomimetic modelsIn vitro-in vivo correlationTherapeutic-window evidence
Evidence path
- Target effect at a lower total dose
- Interpretable systemic exposure
- Local tolerability and device fit
- Candidate and CMC convergence
DISCLOSURE BOUNDARY
Communicating platform value without disclosing reproducible details
Public pages do not disclose molecules, targets, formulation parameters, device parameters, raw data or unpublished IP structures. Deeper discussion proceeds through Partner Access.
BUILD THE NEXT VALUE INFLECTION
Turn the next asset into decision-grade evidence
Connect with BM Pharma on delivery platforms, co-development, translation and strategic partnerships.